NTLA Q3 2022 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+84.1% YoY

Gross Profit

-$83M-628.6% margin

Operating Income

-$106M-795.5% margin

Net Income

-$113M-853.5% margin

EPS (Diluted)

$-1.49

QoQ Revenue Growth

-5.4%

Cash Flow

Operating Cash Flow

-$79M

Free Cash Flow

-$83M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$260M

Stockholders' Equity

$825M

Cash & Equivalents

$141M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$7M	+84.1%
Gross Profit	-$83M	-$53M	-56.5%
Operating Income	-$106M	-$72M	-46.6%
Net Income	-$113M	-$72M	-58.0%